11 April 2017Americas

Novartis and Roxane enter settlement over cancer treatment

Novartis and Roxane Laboratories have entered into a settlement agreement following a patent dispute between the parties over a cancer treatment.

The settlement proposal was filed on April 3 at the US District Court for the District of Delaware.

Judge Leonard Stark signed the settlement on Wednesday, April 5, dismissing the case without prejudice and instructing each party to cover its own attorneys’ fees.

Novartis had filed a complaint against Roxane in October 2015, alleging that Roxane was infringing its drug Gleevec (imatinib mesylate) by filing an Abbreviated New Drug Application with the Food and Drug Administration.

Gleevec is used to treat certain types of leukemia, bone marrow disorders, skin cancer, and certain tumours of the stomach and digestive system.

The two patents involved were US numbers 6,894,051 and RE43,932.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at